8-KEarnings & ResultsRegulation FDExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 12, 2016)

Filed January 12, 2016For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. filed this Form 8-K on January 12, 2016, to announce upcoming presentations at the 34th Annual J.P. Morgan Healthcare Conference. The primary focus for investors is the expected disclosure of preliminary full-year 2015 U.S. and global net sales for their key drug, EYLEA® (aflibercept). These presentations, scheduled for January 13, 2016, will feature updates from Regeneron's CEO, Dr. Leonard S. Schleifer, and CFO, Robert E. Landry. The market will be closely watching these figures to gauge EYLEA's commercial performance and its contribution to the company's overall financial health heading into 2016. The filing also notes that the information provided in these presentations will not be deemed "filed" for SEC purposes, meaning it's a voluntary update.

Key Highlights

  • 1Regeneron will provide preliminary full-year 2015 U.S. net sales for EYLEA® at the J.P. Morgan Healthcare Conference.
  • 2Preliminary global net sales for EYLEA® for the full year 2015 will also be disclosed.
  • 3The company's CEO and CFO will be presenting updates on January 13, 2016.
  • 4The filing includes furnished presentations as exhibits, offering detailed insights into EYLEA sales and a 2016 financial overview.
  • 5This report serves as a communication vehicle for investor updates during a major industry conference.
  • 6Information presented is furnished and not deemed 'filed' under Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform investors that Regeneron Pharmaceuticals, Inc. will be presenting preliminary sales data for EYLEA® and providing a financial overview at the 34th Annual J.P. Morgan Healthcare Conference on January 13, 2016. The company is furnishing copies of these presentations as exhibits to the filing.

The company will release preliminary, unaudited U.S. net sales for EYLEA® for the full year 2015, as well as preliminary global net sales for EYLEA® for the full year 2015. A separate presentation will provide a '2016 Financial Overview'.

No, the information included or incorporated by reference in Item 2.02 and Item 7.01 of this Current Report, including the furnished exhibits, shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, unless expressly stated otherwise in a future filing.

The presentations are scheduled to take place on January 13, 2016, at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California. One presentation will be a corporate update by the CEO, and another will be a '2016 Financial Overview' by the CFO at a sell-side investor meeting.